Exome scale map of genetic alterations promoting metastasis in colorectal cancer

Krzysztof Goryca 1*, Maria Kulecka 2, Agnieszka Paziewska 2, Michalina Dabrowska 1, Marta Grzelak 3, Magdalena Skrzypczak 3, Krzysztof Ginalski 3, Andrzej Mroz 4, Andrzej Rutkowski 5, Katarzyna Paczkowska 1, Michal Mikula 1 and Jerzy Ostrowski 1

Abstract

Background: Approximately 90% of colorectal cancer (CRC) deaths are caused by tumors ability to migrate into the adjacent tissues and metastasize into distant organs. More than 40 genes have been causally linked to the development of CRC but no mutations have been associated with metastasis yet. To identify molecular basis of CRC metastasis we performed whole-exome and genome-scale transcriptome sequencing of 7 liver metastases along with their matched primary tumours and normal tissue. Multiple, spatially separated fragments of primary tumours were analyzed in each case. Uniformly malignant tissue specimen were selected with macrodissection, for three samples followed with laser microdissection.

Results: > 100 sequencing coverage allowed for detection of genetic alterations in subpopulation of tumour cells. Mutations in KRAS, APC, POLE, and PTPRT, previously associated with CRC development, were detected in most patients. Several new associations were identified, including PLXND1, CELSR3, BAHD1 and PNPLA6.

Conclusions: We confirm the essential role of inflammation in CRC progression but question the mechanism of matrix metalloproteinases activation described in other work. Comprehensive sequencing data made it possible to associate genome-scale mutation distribution with gene expression patterns. To our knowledge, this is the first work to report such link in CRC metastasis context.

Keywords: Colorectal cancer, Metastasis, Exome, Gene expression, Sequencing

Background

High mortality rate of colorectal cancer stems from its metastatic potential [1]. Metastasis is also crucial health problem for other tumours - it causes 90% of deaths for all solid tumours [2]. Recently great progress has been made in the understanding of biological principles of the metastatic process [3], which translated into new therapies extending patient survival over twofold [4]. Further advances in clinical treatment are hampered by genetic heterogeneity and evolutional potential of lesions. Genotyping of single variant or even single whole gene is often insufficient to predict effectiveness of molecularly targeted therapies and we still lack the thorough atlas of underlying genetic aberrations.

The development of primary colorectal tumour (PT) occurs along well described sequence of genomic mutations. The most essential are alterations in APC, TP53, KRAS, PIK3CA and TGFB, but many others have been detected - 46 genes have been causally linked to the development of CRC according to the Catalogue Of Somatic Mutations In Cancer (COSMIC) database [5]. In contrast, no mutations have been associated with metastasis yet [6].

There are two possible reasons of the failure of previous work [7, 8] to demonstrate genetic causal link to metastasis. The first one is the molecular heterogeneity of cancer specimen studied. Metastatic lesions (MT) have been shown to harbour from less than 10 to more than 800 somatic mutations in the exomic region [7]. The molecular features of primary tumours are also highly inconsistent which led to selection of distinct subclasses [9]. There may be multiple paths leading to
dissemination into distant locations for each subclass of primary tumour, making published studies underpowered. Secondly, metastasis may be purely stochastic process, independent of specific genetic traits present in the primary lesion. Factors outside cancerous cells, like immunological response, relative position of primary tumour in respect to existing vasculature and susceptibility of vascular epithelia to invasion may contribute to metastasis, greater than any single genetic mutation.

There are three aspects of metastasis genetics that are yet to be explained: which alterations are key drivers of the process, in what mechanism they occur and what functions/aspects of cell do they modify. The first problem is complicated by the fact that multiple distinct DNA modifications can lead to similar phenotype, which increases sample size required to prove causal link. Functional alterations are yet impossible to decrypt on genomic scale with genotype alone and without broad information on gene expression.

Here we employ next generation sequencing for both, exome genotyping and transcriptome sequencing of freshly frozen samples sets (normal tissue, primary tumour and liver metastasis) from 7 patients to characterise mutational landscape of metastatic CRC.

Methods

Tissue specimen

Primary colon tumours with normal tissue margin and slices of liver metastases less than 1 mm thick and less than 10 mm long were dissected simultaneously. Parts of both were used for immediate pathology examination and the rest was frozen in -80 °C upon further processing.

For primary tumours, sections of uniformly malignant tissue were selected in macro-dissection procedure. For 5 primary tumours further dissection of multiple spatially separated fragments of malignant tissue was conducted to assess intra-tumour variability. For three primary tumours, microdissection was performed using PALM laser microdissection and pressure catapulting (LMPC) system (PALM MicroBeam with PALM RoboMover module and PALM RoboSoftware; Carl Zeiss Microlmaging GmbH, Germany) (samples 10PT3, 10PT4, 5PT1, 5PT2, 9PT4, 9PT5).

The extraction and purification of DNA was performed using QIAamp DNA Micro Kit (Qiagen, Germany) according to Protocol for Isolation of Genomic DNA from Laser-Microdissected Tissues. DNA sample concentration was measured using NanoDrop spectrophotometer, following the manufacturer’s instructions. DNA was further stored at -20 °C.

Exome sequencing

Exome libraries were generated using Nextera Rapid Capture Expanded Exome Enrichment Kit (Illumina). Sequencing (2x94bp or longer) was performed using Illumina HiSeq 2500 system with TruSeq PE Cluster Kit v3 and SBS Kit v3(Illumina). The sequencing quality was evaluated with FastQC (http://www.bioinformatics.babraham.ac.uk/ projects/fastqc). Sequences were obtained using the Solexa Analysis Pipeline and mapped to the human genome assembly (hg19) using Bowtie2 (version 4.1.2 [10]). Variants differentiating tumours and respective normal tissue were called using Varscan2 (version 2.3.7 [11]). Short and medium structural variants were detected using Pindel (version 0.2.4t [12]). Called single nucleotide variants were filtered with fpfilter (https://github.com/ckandoth/variant-filter/blob/master/fpfilter.pl) using default parameters with the exception of minimal allele fraction set to 0.1 (min-var-frac = 0.1).

Annovar (version 20,150,617 [13]) was used to annotate variants with genes, position respective to genes (exonic/intronic/splicing/translated region (UTR)/upstream/downstream/intergenic), impact on protein sequence (synonymous/ nonsynonymous/stopgain/stoploss) and identify variants previously linked to CRC development according to International Cancer Genome Consortium (ICGC, version 21). Frequencies of minor allele in the 1000 Genomes Project database, Exome Sequencing Project of National Heart, Lung, and Blood Institute (6500 exomes, [14]) and in Exome Aggregation Consortium database (ExAC, >60,000 exomes, [15]) were also annotated using Annovar. To exclude common variants, homozygous non-reference variants present in more than 50% population according to ExAC database were removed.

Variants previously linked to CRC development were imported from COSMIC database (version 20,161,128 [5]). “Filtered variants” sets were created in three consecutive steps. First, variants differentiating tumour and normal tissue were called with Varscan2. Detected variants were then filtered according to read depth (> = 20) and number of non-reference reads from each strand (> = 4). Last, variants detected in more than 1% of population according to ExAC, 6500 exomes or 1000 Genomes Project (both global and European) database were discarded. Exclusive metastatic variants (EMV) were selected in similar way, by further removing variants detected in primary tumours from metastatic variants set.

Functional analysis of EMV was performed with Gene Set Enrichment Analysis (GSEA) software (version 2.2.4, [16]), using Reactome [17] as gene sets database. Two scores were used as gene rankings for GSEA – Cancer-specific High-throughput Annotation of Somatic Mutations (CHASM) [18] for missense driver cancer mutations and highest Combined Annotation Dependent Depletion (CADD) score variant per gene [19] for all the variants.

Transcriptome sequencing

Total RNA was isolated from tissue using RNeasy Plus Mini Kit (Qiagen, Germany), following manufacturer
protocol. The purity and quantity of RNA was measured with NanoDrop spectrophotometer and assessed using an Agilent 2100 Bioanalyzer with RNA 6000 Nano Kit (Agilent, California). Samples were stored at -70 °C.

Sequencing libraries were generated using Ion AmpliSeq Library Kit Plus (Thermo Fisher). Sequencing was performed using Ion Proton instrument with 5 or 6 samples per chip with Ion PI Hi-Q Sequencing 200 Kit (Thermo Fisher). Reads were aligned to the hg19 AmpliSeq Transcriptome ERCC v1, target panel 21 K v1. Transcripts were quantified with HTseq-count (version 0.6.0 [20]), run with default options. Differentially expressed genes were determined with negative binomial test implemented in DESeq2 package (version 1.12.4, [21]). Patients were used as confounding variable. P-values were corrected for multiple hypotheses testing with Benjamini-Hochberg procedure and differences with corrected p-values < 0.05 were considered significant.

Overrepresentation of Gene Ontology (GO) terms [22] assigned to genes with the most marked expression differences between groups was tested with Fisher Exact test implemented in GOstats package (version 2.40.0, [23]). Tests were performed in the “conditional” mode, separately for biological process and molecular function branch. Only terms with more than 2 and less than 2% of the total number of observed transcribed genes (~20,000) were assessed. P-values from Fisher Exact test were corrected with Benjamini-Hochberg procedure.

The link between transcriptome changes and observed mutations was probed with Kolmogorov-Smirnov test. Genes were sorted according to expression fold-change (FC) between each tumour sample and respective normal sample. Position of genes carrying selected classes of mutations on FC sorted list was used as an input for Kolmogorov-Smirnov test. Analysis was done separately for all non-silent, homozygous non-silent, stopgain and indel mutations.

Availability of data and materials
The dataset supporting the conclusions of this article is available in the Gene Expression Omnibus repository (https://www.ncbi.nlm.nih.gov/geo/) under entry GSE89393.

Results
Exome sequencing
Between 1.5 and 9.7 billion base reads that mapped to the reference genome were generated during exome sequencing for 7 sets of freshly frozen samples (Additional file 1: Table S1). Each set consisted of normal tissue, metastatic tumour and between 1 and 6 samples of primary tumour. Between 54 and 3029 variants differentiating primary tumours and metastases from normal tissue were found (“filtered variants”, Fig. 1). Between 1 and 88 of those variants were stop-gains. Samples could be classified into low and high mutation count categories with between 54 and 306 mutations detected in the former and between 1490 and 3029 in the latter (1–7 and 36–88 stop-gains, respectively). Characteristics of variants detected in metastatic samples closely resembled those of respective primary tumours. 426 filtered variants were detected in more than one patient, 49 were detected in 3 patients and 17 in 4 patients (Additional file 2: Table S2). There were three frameshift substitutions detected simultaneously in 4 patients, in ABTB2, TP11 and GLI2. 6 filtered variants that were homozygous, exonic and nonsynonymous were detected in at least two patients (Additional file 3: Table S3). Frameshift causing insertion of adenine at codon 336 of transcript NM_000365 of TP11 was detected in four patients, three of those insertions were homozygous.

Mutations of C:G pairs were detected over nine times more often than mutations of A:T pairs and three times as many transversions than transitions (Fig. 1). Most of the filtered variants were exonic (46.2%), intronic (14.5%), 3’UTR (11.6%) or intergenic (10.5%), which was in line with library preparation method used. 29.0% of filtered variants were nonsynonymous SNV, 11.4% were synonymous SNV and 2.6% were stopgains according to Annovar (Additional file 4: Table S4).

Numerous variants in genes already implicated in CRC development were detected among filtered variants (Additional file 5: Table S5). Mutation in KRAS was detected in five patients and mutation in APC, POLE and PTPRT was detected in four patients. Notably there were no mutations detected in APC and KRAS in 3 metastatic samples although primary tumours from the same patients were carrying mutations in this genes. In metastases there were between 26 and 2029 variants that weren’t detected in any normal tissue nor in primary tumours (exclusive metastatic variants - EMV). Mutation types were similar to those differentiating primary tumours and normal tissue with C:G pairs substitutions ten times more likely than A:T pair and 4.6 times as many transversions than transitions (Additional file 6: Fig. S2). 47.3% of EMV were exonic, 15.7% intronic, 10.6% 3’UTR and 10.3% were intergenic. 30.9% EMV were nonsynonymous SNV, 10.9% were synonymous SNV and 2.8% were stopgain (Additional file 7: Table S6). The most frequently mutated genes in MT (normalized for length) were NHLH2, RPL13A and SSNA1.

Among variants exclusive to metastatic tumors (EMVs), 89 missense variants are potential cancer drivers (FDR(false discovery rate)-adjusted CHASM p-value < 0.05). Only one variant, BAHD1 p. R533S is present in more than one sample (Additional file 8: Table S7). There are 128 genes, are potential cancer-driver genes (FDR-adjusted CHASM composite p-value < 0.05). None of them is mutated in every sample – the most changed is
PLXND1, with mutation in 5 samples (Additional file 9: Table S8). CELSR3 had EMV in four patients, BAHD1 and PNPLA6 in three. GSEA analysis with CHASM score as ranking feature revealed 5 Reactome pathways with FDR values in 0.05–0.1 range, which included Signaling by FGFR pathway (Additional file 10: Table S9). On the other hand, similar analysis with highest CADD score per gene yielded no significant results (not shown).

**Transcriptome sequencing**

Between 7.8 and 22.4 million of tags read during transcriptome sequencing were mapped to the reference sequence. Between 61.2 and 74.5% of the reference transcripts were detected (Additional file 11: Table S10). There were two outliers among samples according to Principal Component Analysis (PCA), (Additional file 12: Fig. S1). Corresponding samples weren’t taken into account in comparisons between groups.

Expression of 3066 genes was significantly different between normal tissue and primary tumours. 1555/1511 were up/down regulated in tumours. 2677 of them showed at least 2 fold change and 216 over 10 fold change in expression (Additional file 13: Table S11A). There were genes with over 100 fold decrease and over 100 fold increase in expression (Table 1). The most notable examples of down-regulated genes were GUCA2B (FC = 187), TMIGD1 (FC = 129) and CA1 (FC = 121), while CST1 and S100A2 (FC = 131/88.7, respectively) were highly expressed in tumours but not in normal tissue. Differences in expression were attributed to electrolyte homeostasis (GO:0015711, GO:0006811) and some metabolic processes, including lipid and fatty acid metabolism (Table 3A). “Response to drug” (GO:0042493) is particularly interesting in this context because all samples were collected prior to chemotherapeutic treatment. “Magnesium ion binding” (GO:0000287) was the only molecular function overrepresented among the most differentiating genes (adj. p = 0.015, FC = 1.98).

105 genes were differentially expressed between metastases and primary tumours. 38/67 were up/down regulated in metastases. For CRP and FGG expression increased over 50-fold (Table 2, Additional file 13: Table S11B). The most overrepresented biological processes among differentiating genes were cellular component and extracellular matrix organization, followed by immune response-related processes (Table 3B). Interestingly, neither EGFR nor EGF, previously proposed as essential for matrix organization [24], were found to be differentially expressed. The most significant molecular function was “heparin binding” and several extracellular matrix remodelling processes (Additional file 14: Table S12).

GO biological processes with the highest overrepresentation in the 10% of genes with the lowest p-value (selected subset) in comparison between normal colon vs primary tumour (A) or primary tumour vs metastases (B). Count - number of genes in selected subset attributed to a given GO term. Expected count - number of genes expected to be attributed to given category by chance.
The aggregated effect of accumulated mutations was visible in the observed transcriptome remodelling. When genes were sorted according to fold-change of expression (FC) for three pairs of tumour-normal sample, the genes with detected filtered variants weren’t distributed randomly. For various classes of filtered variants there was a significant bias of distribution along FC-sorted genes detected with Kolmogorov-Smirnov test (bold highlight in Table 4). Differences in one MT transcriptome vs respective normal tissue were linked to the set of all non silent mutations. Interestingly, stop-gains were less impactful on their own, with significant association

| RefSeq ID | gene symbol | gene name                                      | FC    | adjusted p-value |
|-----------|-------------|-----------------------------------------------|-------|-----------------|
| NM_001898 | CST1        | cystatin SN                                   | 131.6 | 3E-25           |
| NM_005078 | S100A2      | S100 calcium binding protein A2               | 88.7  | 1.45E-27        |
| NM_182507 | KRT80       | keratin 80                                    | 52.9  | 8.81E-21        |
| NM_178493 | NOTUM       | NOTUM, palmitoleoyl-protein carboxylesterase  | 46.6  | 3.01E-17        |
| NM_005069 | SIM2        | single-minded family bHLH transcription factor 2 | 44.2  | 1.15E-18        |
| NM_001201 | BMP3        | bone morphogenetic protein 3                  | 0.0217 | 3.34E-15       |
| NM_182546 | YSTM2A      | V-set and transmembrane domain containing 2A  | 0.0170 | 6.77E-14       |
| NM_001169 | AQP8        | aquaporin 8                                   | 0.0169 | 3.01E-17        |
| NM_001285 | CLCA1       | chloride channel accessory 1                  | 0.0164 | 5.46E-17        |
| NM_152338 | ZG16        | zymogen granule protein 16                    | 0.0142 | 2.53E-14        |
| NM_000067 | CA2         | carbonic anhydrase 2                          | 0.0135 | 2.33E-42        |
| NM_001812 | CA7         | carbonic anhydrase 7                          | 0.0129 | 9.63E-16        |
| NM_0012374 | SLC4A4      | solute carrier family 4 member 4              | 0.0120 | 2.19E-27        |
| NM_0012883 | CA1         | carbonic anhydrase 1                          | 0.0083 | 9.96E-18        |
| NM_206832 | TMIGD1      | transmembrane and immunoglobulin domain containing 1 | 0.0078 | 7.55E-21        |
| NM_007102 | GUC2A2B     | guanylate cyclase activator 2B                | 0.0053 | 1.03E-30        |

FC - fold change (expression in primary tumours/expression in normal colon)

| RefSeq ID | gene symbol | gene name                  | FC    | adjusted p-value |
|-----------|-------------|----------------------------|-------|-----------------|
| NM_005677 | CRP1        | C-reactive protein         | 85.0  | 2.36E-21        |
| NM_021870 | FGG         | fibrinogen gamma chain     | 56.0  | 1.98E-12        |
| NM_00124070 | GC       | GC, vitamin D binding protein | 29.1  | 1.19E-08        |
| NM_002216 | ITIH2       | inter-alpha-trypsin inhibitor heavy chain 2 | 26.1  | 1.43E-06        |
| NM_005141 | FGB         | fibrinogen beta chain      | 25.1  | 4.18E-05        |
| NM_000424 | APOH        | apolipoprotein H           | 22.2  | 4.18E-05        |
| NM_002215 | ITIH1       | inter-alpha-trypsin inhibitor heavy chain 1 | 22.0  | 1.81E-05        |
| NM_000677 | ORM1        | orosomucoid 1              | 16.0  | 8E-06           |
| NM_004467 | FGL1        | fibrinogen like 1          | 14.2  | 0.003387        |
| NM_001063 | TF          | transferrin                | 12.9  | 0.000902        |
| NM_001250 | F12         | coagulation factor XII     | 12.3  | 0.003333        |
| NM_145285 | NIXO2-3     | NK2 homeobox 3             | 0.055 | 2.63E-07        |
| NM_003405 | MFAP5       | microfibrillar associated protein 5 | 0.068 | 6.59E-05        |
| NM_004950 | EPOC        | epiphycan                  | 0.070 | 0.001189        |
| NM_002148 | HOXD10      | homeobox D10               | 0.071 | 7.38E-05        |
| NM_001170807 | FHL5   | four and a half LIM domains 5 | 0.078 | 4.18E-05        |
| NM_00145311 | PLIN1     | perilipin 1                | 0.080 | 0.001189        |
| NM_019849 | SLC7A10     | solute carrier family 7 member 10 | 0.080 | 0.00042         |

FC - fold change (expression in metastases/expression in primary tumours)
with transcriptome changes only in one primary and none of metastatic tumours (Table 4).

**Discussion**

Contrary to previously published results [7], where transversions were less prevalent than transitions by twofold, there were 3 times more transversions than transitions. The number of detected somatic variants was, on average, more than two times higher here than in Lim B et al. [7]. Discrepancies cannot be explained neither by sequencing technology (Illumina HiSeq in both cases), nor by sequencing depth, which was similar (101 vs 133). Mapping software was also comparable (BWA [25] vs Bowtie 2). The most significant protocol difference is that we used Varscan2 [11] instead of MuTect [26]. Varscan2 is more sensitive than MuTect, detecting over 3 times more SNP in some scenarios [27]. Furthermore, MuTect misses some high quality variants [28]. We believe that Mutect is overly conservative, especially when sequencing depth is high (> 100). Additional filtering for minimal number of reads from each strand (>= 4) supporting variant protect against high false-positive rate. Contradicting results on mutation type distribution highlight the dependence of conclusions regarding mutation mechanism on analytic choices.

There were 89 cancer-driver mutations among EMVs predicted by CHASM, however most of them concerned only one tumour. On the other hand, on gene level there were 128 cancer-driver genes predicted, two mutated in four patients and one in five. Moreover, GSEA analysis revealed significant enrichment of FGFR signalling and

**Table 3** GO terms significant for normal colon - primary tumour - metastasis transition

| GO ID     | GO name                                  | adjusted p-value | count | expected count |
|-----------|------------------------------------------|------------------|-------|----------------|
| A         |                                          |                  |       |                |
| GO:0015711| organic anion transport                   | 3.64E-03         | 51    | 25.2           |
| GO:0006811| ion transport                             | 3.64E-03         | 44    | 20.8           |
| GO:0034440| lipid oxidation                          | 6.15E-03         | 27    | 10.5           |
| GO:0061326| renal tubule development                  | 2.46E-02         | 24    | 9.7            |
| GO:0006730| one-carbon metabolic process              | 2.46E-02         | 11    | 2.7            |
| GO:0042493| response to drug                         | 2.46E-02         | 54    | 30.6           |
| GO:0006635| fatty acid beta-oxidation                 | 4.01E-02         | 12    | 3.3            |
| GO:0030214| hyaluronan catabolic process              | 4.13E-02         | 8     | 1.6            |
| GO:0072163| mesonephric epithelium development        | 4.13E-02         | 24    | 10.3           |
| B         |                                          |                  |       |                |
| GO:0016043| cellular component organization           | 1.03E-03         | 42    | 18.3           |
| GO:0030198| extracellular matrix organization         | 3.29E-03         | 40    | 18.1           |
| GO:0002576| platelet degranulation                    | 3.72E-03         | 28    | 10.9           |
| GO:0006953| acute-phase response                      | 3.72E-03         | 17    | 4.9            |
| GO:0034367| macromolecular complex remodeling         | 1.67E-02         | 11    | 2.6            |
| GO:0010951| negative regulation of endopeptidase activity | 1.81E-02     | 27    | 11.5           |
| GO:0044057| regulation of system process              | 1.81E-02         | 60    | 35.1           |
| GO:0007204| positive regulation of cytosolic calcium ion concentration | 1.81E-02 | 45 | 24.0 |
| GO:0006559| L-phenylalanine catabolic process         | 2.45E-02         | 7     | 1.2            |

**Table 4** Assessment of transcription changes of genes with given alterations in the coding sequences

| Sample ID | 10.PT1 | 10.PT2 | 10.PT3 | 10.PT4 | 10.PT5 | 10.PT6 | 10.MT | 5.MT | 7.PT1 | 7.PT2 | 7.PT3 | 7.PT4 | 7.MT | 12.PT | 12.MT |
|-----------|--------|--------|--------|--------|--------|--------|-------|------|-------|-------|-------|-------|------|-------|-------|
| stopgain  | 0.6    | 0.9    | 0.6    | **1.9**| 0.3    | **1.4**| 0.2   | 0.3  | 0.1   | 0.1   | 1.1   | 0.1   | 0.4  |
| non silent| **7.4**| **8.1**| **7.5**| **8.8**| **4.5**| **6.9**| 0.7   | 0.5  | 0.5   | 0.0   | 0.2   | 1.3   | 0.4  | Inf   | 2.1   |
| silent exonic | 1.7 | 1.2    | 3.8    | 4.4    | 1.1    | 3.0    | 0.1   | 0.3  | 0.1   | 0.3   | 0.4   | 0.6   | **1.5**| 8.2   | 1.2   |
| indels all | 0.2    | 0.6    | 0.8    | 0.2    | 1.0    | 0.7    | 0.3   | 0.3  | **3.3**| 0.5   | 0.4   | 0.3   | 0.0  | **2.3**| 0.1   |

Given values are -log10 of p-value from Kolmogorow-Smirnoff test of altered vs non-altered genes (see methods). Bold highlights significant association (values greater than -log10(0.05)). Inf - values greater than 10.
antigen processing pathways. These results suggest indeed there are no specific mutations involved in metastatic processes, however the cancer-driver mutation distribution is not entirely random since it involves specific genes and pathways.

High levels of CRP, the gene with the most significant expression increase in liver metastases (Table 2), were previously associated with poorer prognosis for CRC [29, 30]. This is in line with other findings associating various inflammation symptoms with metastasis (Table 3) [31]. The key players in inflammation progression are matrix metalloproteinases (MMP) well described in the CRC context [32] and significantly differentiating primary tumour from normal tissue here (Additional file 13: Table S11). EGFR was labelled MMP regulator [24] and was found downregulated in lymph node metastasis vs primary tumours [33]. In our study neither EGF nor EGFR expression did differentiate metastasis from primary tumour, which suggests there is other mode of MMP activation.

Conclusions
Seven sample sets are, like in previous work [7, 8], not enough to prove any direct genetic linkage to metastatic process. Transcriptome sequencing however, revealed some tissue remodelling and immune processes essential for metastasis (Table 3, Additional file 14: Table S12). Furthermore, we were able to associate observed remodelling of transcription in both primary and metastatic tumours with accumulated mutations (Table 4). This supports the thesis that widespread genetic instability generates the environment for evolutionary selection of tumour cells and is the driver of malignancy.

Additional files

Additional file 1: Table S1. Sequencing parameters for 3 samples with the highest and 3 samples with the lowest sequencing yield, along with the mean and median of sequencing parameters for all (31) samples. (DOCX 12 kb)

Additional file 2: Table S2. Filtered variants detected in three or more patients. Chromosome, start, end - genome coordinates of variant; Refer/Alt - reference/alternative variant sequence; GT - genotype detected in a given sample (0 - reference, 1 - alternative). DP - number of high quality reads at a given position in a given patient. FuncrefGene - location of variant relative to gene. Gene - symbol of a gene the given variant maps to, or names of genes the given variants maps in between. GeneDetails - refGene - refSeq gene ID or distance to nearest gene given in the “Gene” column. EsAC, XXX - frequency of the alternative variant in XXX population according to EsAC database. 1000Gg_all/exor - variant frequency in the 1000 Genomes Project database (total/European). esp6500siv2_all - variant frequency according to ExAC database. 1000Gg_all/exor - variant frequency in the 1000 Genomes Project database (total/European). esp6500siv2_all - variant frequency according to ExAC database. (XLSX 34 kb)

Additional file 3: Table S3. Homozygous, exonic and nonsynonymous filtered variants that were detected in more than one patient. Column description is the same as in Additional file 2: Table S2. (XLSX 11 kb)

Additional file 4: Table S4. Functional impact of filtered variants on protein coding sequences. (XLSX 9 kb)

Additional file 5: Table S5. Filtered variants detected in genes implicated in CRC development according to COSMIC database. Four consecutive panels describe zygosity (“GT/sample_name”), impact on protein structure and function (“ExonicFunc_sample_name”), sequencing depth (“DP/sample_name”) and genomic position (“POS/sample_name”). Each field may contain more than one entry if multiple variants were detected in one gene. Red/orange fields denotes homozygous/heterozygous variants. If one of multiple variants was homozygous given field was marked red. Primary/metastatic samples were marked yellow/red, respectively. (XLSX 27 kb)

Additional file 6: Figure S2. Mutation types in EMV in freshly frozen samples. Transitions and transversions are given total for all single nucleotide substitutions. (TIFF 427 kb)

Additional file 7: Table S6. Functional impact of EMV on protein coding sequences. (XLSX 9 kb)

Additional file 8: Table S7. EMV Cancer driver mutations according to CHASM algorithm. Chrom - chromosome number, Position - mutation position, Ref - reference base, Alt - variant base, Sample.ID - sample with mutation, HUGO symbol - HUGO gene symbol, Protein.sequence.change - amino-acid change. CHASM.p.value - p-value for CHASM, dbSNP - identifier in dbSNP, 1000G_genomes/ESP6500/SExAC - allele frequencies in different exome-sequencing projects, COSMICID - COSMIC identifier, Occurrences.in.COSMIC.by.primary.sites - organs, harboring somatic mutations in this gene in COSMIC database, ClinVar.ClinicalSignificance - ClinVar clinical significance, Number.of.Samples - number of samples with mutation, Qvalue - CHASM.p.value corrected for multiple testing with FDR method (XLSX 291 kb)

Additional file 9: Table S8. CHASM cancer-driver identification results for whole genes, where HUGO.symbol - HUGO gene symbol, Number.of.variants - number of variants per gene, Most.severe.sequence.ontology - most severe mutation consequence within gene, CHASM.score - CHASM score for whole gene, CHASM.composite.p.value - composite p-value for whole gene, Qvalue - CHASM.composite.p.value corrected for multiple testing with FDR method, Drivergenes - whether a gene is a driver or tumor-suppressor gene (TSG), Occurrences.in.COSMIC.by.primary.sites - organs, harboring somatic mutations in this gene in COSMIC database, Number.of.samples - number of samples with driver mutation in this gene, TCGA.Mutation.Cluster - whether a TCGA mutation cluster is present within a gene. (XLSX 186 kb)

Additional file 10: Table S9. GSEA results in which CHASM score for a gene was taken as a ranking metric where NAME - Reactome pathway name, SIZE - size of a dataset after subtraction of genes not present in ranked set, ES/NES - enrichment score/normalized enrichment score, NOM p-value - nominal p-value, FDR - false discovery rate, LEADING EDGE - statistics used to define the leading edge subset (for details, please refer to http://software.broadinstitute.org/gsea/doc/GSEAUserGuideDECTEXT.htm#_GSEA_Report). (XLSX 15 kb)

Additional file 11: Table S10. Sequencing summary for the transcriptome profiling. Valid read - fraction of reads meeting quality standard, on target - fraction of valid reads mapping to the part of genome targeted by employed primers. (XLSX 9 kb)

Additional file 12: Figure S1. Plot of the first four principal components (PC) for gene expression according to RNA-Seq. Result for all samples (A, top panels) and after removal of two outliers (B, bottom panels). All axes depict arbitrary units. (TIF 1016 kb)

Additional file 13: Table S11. Results of RNA expression comparison between normal colon tissue and primary tumour (A) and between primary tumours and metastases (B). Target - the producers (Life Technologies) id of respective amplicon, padj - p-value adjusted for multiple hypotheses testing with Benjamin-Hochberg algorithm. (XLSX 2856 kb)

Additional file 14: Table S12. GO terms (molecular function branch) with the highest overrepresentation in the 10% of genes with the lowest
Abbreviations
CADD: Combined Annotation Dependent Depletion; CHASM: Cancer-specific High-throughput Annotation of Somatic Mutations; COSMIC: Catalogue Of Somatic Mutations In Cancer; CRC: colorectal cancer; DP: sequencing depth; EMV: exclusive metastatic variants; ExAc: Exome Aggregation Consortium database; FC: fold-change; FDR: false discovery rate; GO: Gene Ontology; GSEA: gene set enrichment analysis; GT: genotype; ICGC: International Cancer Genome Consortium; LMPC: laser microdissection and pressure catapulting; MMP: matrix metalloproteinases; MT: metastatic tumour; PCA: principal component analysis; PT: primary tumour; UTR: untranslated region

Funding
This study was funded by the National Science Center, grant numbers 2012/05/D/N22/01623. KG2 was supported by the National Science Center (2011/02/A/N22/00014) and the Foundation for Polish Science (TEAM). MS was supported by the National Science Center (2015/17/D/N22/03711). The funders had no role in the study design, data collection, analysis and interpretation, decision to publish, or preparation of the manuscript.

Availability of data and materials
The dataset supporting the conclusions of this article is available in the Gene Expression Omnibus repository (https://www.ncbi.nlm.nih.gov/geo/) under entry GSE89393.

Ethics approval and consent to participate
The study was approved by the ethics committee (decision KB 3/2013) of Maria Sklodowska-Curie Memorial Cancer Centre, Warsaw, Poland. All participants provided written informed consent. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki.

Consent for publication
Not applicable.

Competing interests
None of the authors have any competing interests regarding presented work.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Genetics, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.
2Department of Gastroenterology, Hepatology and Clinical Oncology, Medical Center for Postgraduate Education, Warsaw, Poland.
3Laboratory of Bioinformatics and Systems Biology, Center of New Technologies, University of Warsaw, Warsaw, Poland.
4Department of Patomorphology, Medical Center for Postgraduate Education, Warsaw, Poland.
5Department of Oncological Gastroenterology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.

References
1. Elferink MAG, de Jong KP, Klaase JM, Siemerink EJ, de Wilt JHW. Metachronous metastases from colorectal cancer: a population-based study in north-East Netherlands. Int J Color Dis. Feb. 2015;30(2):205–12.
2. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. Nov. 2006;127(6):679–95.
3. Langley RR, Figdor L. The seed and soil hypothesis revisited—the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer. Jun. 2011;128(11):2527–35.
4. Grothey A, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol Off J Am Soc Clin Oncol. Nov. 2008;26(33):5326–34.
5. Forbes SA, et al. COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015;43(Database issue):D805–11.
6. Vanharanta S, Massague J. Origins of metastatic traits. Cancer Cell. Oct. 2013; 24(4):410–21.
7. Lim B, et al. Genome-wide mutation profiles of colorectal tumors and associated liver metastases at the exome and transcriptome levels. Oncotarget. Sep. 2015;6(26):22179–90.
8. Zehir A, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(6):703–13.
9. Guinney J, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–6.
10. Langmead B, Salzberg SL. Fast gapped-read alignment with bowtie 2. Nat Methods. 2012;9(4):357–9.
11. Koboldt DC, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;22(2):358–76.
12. Ye K, Schulz MH, Long Q, Apweiler R, Ning Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinforma. Oxf. Engl. 2009;25(21): 2865–71.
13. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010; 38(16):e164.
14. Sudmant PH, et al. An integrated map of structural variation in 2,504 human genomes. Nature. 2015;525(7571):78–81.
15. Lek M, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285–91.
16. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50.
17. Fabregat A, et al. The Reactome pathway knowledgebase. Nucleic Acids Res. 2016;44(D1):D481–7.
18. Carter H, et al. Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res. 2009;69(16):6660–7.
19. Kinch C, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46(3):310–5.
20. Anders S, Pyl PT, Huber W. HTSeq—a Python framework to work with high-throughput sequencing data. Bioinforma. Oxf. Engl. 2015;31(2):166–9.
21. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.
22. Ashburner M, et al. Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat Genet. 2000;25(1):25–9.
23. Falcon S, Gentleman R. Using GOstats to test gene lists for GO term association. Bioinforma Oxf. Engl. 2007;23(2):257–8.
24. Kajanne R, et al. EGF-R regulates MMP function in fibroblasts through MAPK and AP-1 pathways. J Cell Physiol. 2007;212(2):489–97.
25. Li H, Durbin R. Fast and accurate long-read alignment with burrows-wheeler transform. Bioinforma. Oxf. Engl. 2010;26(5):589–95.
26. Cibulskis K, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31(3):213–9.
27. Kripář G, Thomassen M, Lænkholm A-V, Kruse TA, Larsen MJ. Evaluation of nine somatic variant callers for detection of somatic mutations in exome and targeted deep sequencing data. PLoS One. 2016;11(3):e0151664.
28. Wang Q, et al. Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers. Genome Med. 2013;5(10):91.
29. Shrotriya S, Walsh D, Bennani-Baiti N, Thomas S, Lorton C. C-reactive protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: a systematic review. PLoS One. 2015;10(12): e0143080.
30. Li C, Xu Q, Chen L, Luo C, Ying J, Liu J. C-reactive protein (CRP) as a prognostic factor for colorectal cancer after surgical resection of pulmonary metastases. Bull Cancer (Paris). 2017;104(3):232–6.
31. Terzić J, Grivennikov S, Kain E, Kain M. Inflammation and colon cancer. Gastroenterology. 2010;138(6):2101–2114.e5.
32. Said AH, Raufman J-P, Xie G. The role of matrix metalloproteinases in colorectal cancer. Cancers. 2014;6(1):366–75.
33. Xie N, Yao Y, Wan L, Zhu T, Liu L, Yuan J. Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer. Exp Ther Med. 2017;14(1):338–43.